Last checked at 22 May 2024 09:53
LONDON BROKER RATINGS: Barclays cuts NextEnergy but lifts JLEN
(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Astrazeneca Share News (AZN)
AZN Share
Price
AZN Share
News
AZN Share
Chat
AZN Share
Trades1
AZN
Live RNS
AZN Share
Charts
AZN Level 2
Console
AZN Live
Share Price
AZN Broker
Ratings
AZN Directors
Deals
AZN Financial
Diary
AZN
Fundamentals
AZN Short
Positions
AZN
Media
Astrazeneca Information
Share Price Information for Astrazeneca (AZN)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
12,404.00
Bid:
11,850.00
Ask:
12,470.00
Change:
0.00 (0.00%)
Spread:
620.00 (5.232%)
Open:
0.00
High:
0.00
Low:
0.00
Prev. Close:
12,404.00
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.US authorities recommend against AstraZeneca flu vaccine
Thu, 23rd Jun 2016 07:32
(ShareCast News) - Pharmaceutical giant AstraZeneca confirmed disappointing news to investors on Thursday, with updated guidance from US regulators recommending against its FluMist Quadrivalent influenza vaccine.The FTSE 100 firm said the updated guidance from the Advisory Committee on Immunization Practices at the Centers for Disease Control and Prevention has recommended against FluMist for the 2016-2017 flu season.It was based on CDC vaccine effectiveness data from the last three flu seasons in the US, which indicated FluMist did not demonstrate statistically significant effectiveness in children aged between two and 17."The US CDC effectiveness data for 2015-2016 season contrast with studies by AstraZeneca as well as preliminary independent findings by public health authorities in other countries," AstraZeneca's board said in a statement."As influenza vaccine effectiveness varies from season to season, it is evaluated in annual observational studies."The CDC states that when there is a good match between the strains in the vaccine and those that circulate during the influenza season, vaccines are typically 50-60% effective," it added.AstraZeneca's board said it is working with the CDC to better understand its data to help ensure eligible patients continue to receive the vaccine in future seasons in the US.US product sales of FluMist Quadrivalent in the 2015 financial year amounted to $206m, with the updated recommendation from regulators expected to result in very limited US demand in the second half of 2016.The firm said it will take an inventory write-down of $80m in the second quarter of the year, though it maintained its full-year financial guidance."The distribution and use of the vaccine in other countries are progressing as planned for the forthcoming influenza season, pending the annual release process from relevant regulatory authorities," the board explained.
More News
22 May 2024 02:00
British firms expecting hard time in China market, lobby group warns
BEIJING, May 22 (Reuters) - British firms expect doing business in China to become harder over the next five years, a British business lobby group said on Wednesday, as Beijing strives to halt a retreat in foreign funds from a market once seen as the engine of global growth.
Read more21 May 2024 19:00
Sector movers: Stocks slip amid light profit-taking
(Sharecast News) - Stocks ended a tad lower as investors waited on a raft of US central bank speakers scheduled for after the close of markets in London.
Read more21 May 2024 17:20
Europe's STOXX 600 ends lower as rate uncertainty prevails
Focus on Fed minutes, Nvidia earnings
*Read more21 May 2024 17:04
LONDON MARKET CLOSE: London dips as eyes turn to UK inflation reading
(Alliance News) - Stock prices in London closed in the red on Tuesday, as investors nervously eye a key UK inflation reading, which could prompt the Bank of England to consider interest rate cuts.
Read more21 May 2024 15:00
London close: Stocks fall ahead of key inflation reading
(Sharecast News) - London stocks ended in negative territory on Tuesday, influenced by the latest UK economic outlook from the International Monetary Fund (IMF) and comments from US Federal Reserve officials.
Read more21 May 2024 12:03
CORRECT: Stocks fall but pound up as IMF ups UK forecast
(Correcting London Stock Exchange index prices.)
Read more21 May 2024 12:00
LONDON MARKET MIDDAY: Stocks fall but pound up as IMF ups UK forecast
(Alliance News) - Stock prices in Europe were lower heading into Tuesday afternoon, with shares in New York also set for a muted open, as a recent rally for equities takes a pause.
Read more21 May 2024 11:23
AstraZeneca aims for $80 bln in total revenue by 2030
Sees $80 bln in 2030 revenue by 2030
*Read more21 May 2024 09:04
LONDON MARKET OPEN: FTSE 100 declines after Asian stocks fall
(Alliance News) - Stock prices in London opened in the red on Tuesday, with some US interest rate cut optimism cooling after hawkish words from Federal Reserve central bankers.
Read more21 May 2024 08:18
TOP NEWS: AstraZeneca eyes new era of growth with bold new revenue aim
(Alliance News) - AstraZeneca PLC on Tuesday set out its ambition to achieve USD80 billion in annual revenue by the end of the decade as it signalled a new "era of growth."
Read more21 May 2024 07:52
LONDON BRIEFING: AstraZeneca plots "new era of growth"; SSP confident
(Alliance News) - London's FTSE 100 is called to open lower on Tuesday, following a mixed close in New York overnight, and tepid trade in Asia.
Read more21 May 2024 07:34
AstraZeneca lays out plans to hit $80bn in revenues by 2030
(Sharecast News) - AstraZeneca has unveiled medium-term growth targets to nearly double group revenues by the end of the decade as it predicts significant growth from existing oncology, biopharmaceuticals and rare disease portfolios.
Read more20 May 2024 11:55
LONDON MARKET MIDDAY: Gold shines amid interest rate cut hopes
(Alliance News) - Stock prices in London got a boost at midday on Monday, as investors eye a key UK inflation reading later in the week, which is expected to show cooling prices.
Read more20 May 2024 08:56
AstraZeneca to build $1.5-bln cancer drug plant in Singapore
Plans to build ADCs manufacturing facility in Singapore
*Read more